These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 30383729)

  • 1. Elagolix (Orilissa)--an oral GnRH antagonist for endometriosis pain.
    Med Lett Drugs Ther; 2018 Sep; 60(1556):158-160. PubMed ID: 30383729
    [No Abstract]   [Full Text] [Related]  

  • 2. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density.
    Carr B; Dmowski WP; O'Brien C; Jiang P; Burke J; Jimenez R; Garner E; Chwalisz K
    Reprod Sci; 2014 Nov; 21(11):1341-51. PubMed ID: 25249568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of elagolix in the treatment of endometriosis.
    Perricos A; Wenzl R
    Expert Opin Pharmacother; 2017 Sep; 18(13):1391-1397. PubMed ID: 28737050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.
    Taylor HS; Giudice LC; Lessey BA; Abrao MS; Kotarski J; Archer DF; Diamond MP; Surrey E; Johnson NP; Watts NB; Gallagher JC; Simon JA; Carr BR; Dmowski WP; Leyland N; Rowan JP; Duan WR; Ng J; Schwefel B; Thomas JW; Jain RI; Chwalisz K
    N Engl J Med; 2017 Jul; 377(1):28-40. PubMed ID: 28525302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis.
    Shebley M; Polepally AR; Nader A; Ng JW; Winzenborg I; Klein CE; Noertersheuser P; Gibbs MA; Mostafa NM
    Clin Pharmacokinet; 2020 Mar; 59(3):297-309. PubMed ID: 31749075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research development of a new GnRH antagonist (Elagolix) for the treatment of endometriosis: a review of the literature.
    Alessandro P; Luigi N; Felice S; Maria PA; Benedetto MG; Stefano A
    Arch Gynecol Obstet; 2017 Apr; 295(4):827-832. PubMed ID: 28255765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain.
    Ezzati M; Carr BR
    Womens Health (Lond); 2015 Jan; 11(1):19-28. PubMed ID: 25581052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral GnRH Antagonist Ovarian Suppression After Escape From GnRH Agonist in Breast Cancer Patients.
    Coyne K; Silverman P; Liu JH
    Clin Breast Cancer; 2020 Oct; 20(5):e551-e554. PubMed ID: 32616435
    [No Abstract]   [Full Text] [Related]  

  • 9. Overview of elagolix for the treatment of endometriosis.
    Melis GB; Neri M; Corda V; Malune ME; Piras B; Pirarba S; Guerriero S; Orrù M; D'Alterio MN; Angioni S; Paoletti AM
    Expert Opin Drug Metab Toxicol; 2016 May; 12(5):581-8. PubMed ID: 27021205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix.
    Struthers RS; Nicholls AJ; Grundy J; Chen T; Jimenez R; Yen SS; Bozigian HP
    J Clin Endocrinol Metab; 2009 Feb; 94(2):545-51. PubMed ID: 19033369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elagolix as a Novel Treatment for Endometriosis-Related Pain.
    Fantasia HC
    Nurs Womens Health; 2019 Aug; 23(4):366-369. PubMed ID: 31276630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elagolix Pharmacokinetic Profiles in Women With Renal or Hepatic Impairment.
    Ng J; Duan WR; Marbury T; Schmidt JM; Klein CE
    Clin Pharmacol Drug Dev; 2019 Nov; 8(8):1053-1061. PubMed ID: 30570832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elagolix for endometriosis: all that glitters is not gold.
    Vercellini P; Viganò P; Barbara G; Buggio L; Somigliana E;
    Hum Reprod; 2019 Feb; 34(2):193-199. PubMed ID: 30551159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of the oral gonadotropin-releasing hormone-antagonist elagolix for the management of endometriosis-associated pain.
    Taylor HS; Dun EC; Chwalisz K
    Pain Manag; 2019 Sep; 9(5):497-515. PubMed ID: 31434540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elagolix: First Global Approval.
    Lamb YN
    Drugs; 2018 Sep; 78(14):1501-1508. PubMed ID: 30194661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies.
    Surrey E; Taylor HS; Giudice L; Lessey BA; Abrao MS; Archer DF; Diamond MP; Johnson NP; Watts NB; Gallagher JC; Simon JA; Carr BR; Dmowski WP; Leyland N; Singh SS; Rechberger T; Agarwal SK; Duan WR; Schwefel B; Thomas JW; Peloso PM; Ng J; Soliman AM; Chwalisz K
    Obstet Gynecol; 2018 Jul; 132(1):147-160. PubMed ID: 29889764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elagolix Suppresses Ovulation in a Dose-Dependent Manner: Results From a 3-Month, Randomized Study in Ovulatory Women.
    Archer DF; Ng J; Chwalisz K; Chiu YL; Feinberg EC; Miller CE; Feldman RA; Klein CE
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31650182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elagolix sodium for the treatment of women with moderate to severe endometriosis-associated pain.
    Barra F; Scala C; Ferrero S
    Drugs Today (Barc); 2019 Apr; 55(4):237-246. PubMed ID: 31050692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis.
    Surrey ES; Soliman AM; Agarwal SK; Snabes MC; Diamond MP
    Fertil Steril; 2019 Aug; 112(2):298-304.e3. PubMed ID: 30992150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis-Associated Pain: An Application of Markov Model.
    Winzenborg I; Polepally AR; Nader A; Mostafa NM; Noertersheuser P; Ng J
    CPT Pharmacometrics Syst Pharmacol; 2020 Aug; 9(8):466-475. PubMed ID: 32621325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.